Hepatocellular carcinoma (HCC), the main type of primary liver cancer, constitutes the sixth
most common and third most deadly cancer worldwide, respectively. Due to the late …

Despite pharmacological advances such as lenvatinib approval, therapeutic failure of
hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its …

Abstract Neuropilin-1 (NRP-1) participates in the progression of cholangiocarcinoma (CCA)
and lenvatinib is an approved tyrosine kinase inhibitor treating several other cancers. Our …

Results Page 1 ILC2022 Scan to download the poster #ILSa THE INTERNA TIONAL TM LIVER
CONGRESS P. FERNÁNDEZ-PALANCA1,2, T. PAYO-SERAFÍN1,2, F. FONDEVILA1,2, C …

Background Hepatocellular carcinoma (HCC) represents the third most deadly cancer
worldwide with still high therapeutic failure and recurrence rates mainly associated with the …

Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide
and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and …

Background It has been reported that the combination of lenvatinib, a multiple receptor
tyrosine kinase inhibitor, and an immune checkpoint inhibitor enhances the antitumor activity …

Nuclear factor-kappa B (NF-κB), an oncogenic transcription factor, modulates tumor
formation and progression by inducing the expression of oncogenes involved in …

Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers
in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib …

OBJECTIVES: Biomarkers for optimizing the outcome of treatment with lenvatinib in patients
with advanced hepatocellular carcinoma remain to be established despite intensive and …